I-immunotherapy entsha yonyango lwe-peanut allergy

I-Aravax, inkampani ye-biotechnology yesigaba seklinikhi egxile ekuphuhliseni unyango lokuqala lwe-peanut allergy eyenzelwe ukuba ikhuseleke, isebenze kwaye isebenziseke, namhlanje ibhengeza ukuba ifumene ukukhanya okuluhlaza kwisicelo sayo soPhando lweziyobisi (IND) kwi-US Food and Ulawulo lweziyobisi (FDA).

I-PVX108 sisizukulwana esilandelayo, i-allergen-specific immunotherapy isebenzisa i-peptides emele amaqhekeza abalulekileyo e-peanut proteins ukujolisa ngokuchanekileyo iiseli ze-T eziqhuba ukwaliwa kwamandongomane. Ukulawulwa kanye ngenyanga, unyango lwenzelwe ukuba ngokuchanekileyo unyamezelo kwiprotein yamandongomane ngaphandle kweenkxalabo zokhuseleko ezithintela ukusetyenziswa konyango olubhalisiweyo kuphela olusebenzisa izicatshulwa zendalo ezivela kumantongomane. Ubukho bepeanut allergens kwezo zicatshulwa bubeka izigulane kumngcipheko omkhulu we-anaphylaxis (Chu et al. I-Lancet 2019).

I-IND iya kuvumela i-Aravax ukuba iqhubele phambili inkqubo yovavanyo lwekliniki yeSigaba se-2 kwi-US kwaye yandise imisebenzi yayo yehlabathi.

"Siyavuya ukwabelana ngokuba i-FDA ivumele i-Aravax ukuba iqalise uphononongo olusebenzayo lweSigaba se-2 ukuchonga idosi efanelekileyo ye-PVX108 kubantwana abane-peanut allergy e-United States. Lo ngummandla wonyango awugcinwanga ngokwaneleyo, kwaye sikholelwa ukuba indlela yethu inenzuzo ebalulekileyo kunyango olukhoyo ngendlela echanekileyo yokwenza kunye neprofayile yokhuseleko esele ibonakalisiwe kwiSigaba soku-1 solingo lwezonyango. utshilo umphathi weAravax, uGqirha Pascal Hickey.

Ngaphambili, uvavanyo lweSigaba se-1 esilawulwa ngokungahleliwe, oluyimfama oluphindwe kabini, olulawulwa yi-placebo kwi-66 ye-peanut-allergies abadala (AVX-001) alubonisi ubungqina beziganeko ezimbi zokukhathazeka kweklinikhi. Ukongeza, izifundo ze-ex vivo ezibonelela ngomlinganiselo wokhuseleko (i-basophil activation) kwi-185 yabanikeli begazi le-peanut-aleji iqinisekisa ukungabikho kwe-basophil reactivity kwi-PVX108 ngokungafaniyo ne-peanut extract. Ezi datha zibonisa ukuba i-PVX108 ineprofayili yokhuseleko ethandwa kakhulu kunyango lwezigulana ezichasene ne-peanut, kubandakanywa nezo zinokwalisa kakhulu.

I-patent yokuqala ye-Aravax egquma i-lead composition PVX108 nayo inikezelwe e-US, EU nakwamanye amagunya. Iintsapho ezongezelelweyo zelungelo elilodwa lomenzi wechiza nazo ziqhuba kakuhle kwezi ndawo.